Structure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle.

Verschueren, Koen H G; Blanchet, Clement; Felix, Jan; Dansercoer, Ann; De Vos, Dirk; Bloch, Yehudi; Van Beeumen, Jozef; Svergun, Dmitri et al. · Nature · 2019

basic_science · Level V

Where this comes from

Abstract

Across different kingdoms of life, ATP citrate lyase (ACLY, also known as ACL) catalyses the ATP-dependent and coenzyme A (CoA)-dependent conversion of citrate, a metabolic product of the Krebs cycle, to oxaloacetate and the high-energy biosynthetic precursor acetyl-CoA<sup>1</sup>. The latter fuels pivotal biochemical reactions such as the synthesis of fatty acids, cholesterol and acetylcholine<sup>2</sup>, and the acetylation of histones and proteins<sup>3,4</sup>. In autotrophic prokaryotes, ACLY is a hallmark enzyme of the reverse Krebs cycle (also known as the reductive tricarboxylic acid cycle), which fixates two molecules of carbon dioxide in acetyl-CoA<sup>5,6</sup>. In humans, ACLY links carbohydrate and lipid metabolism and is strongly expressed in liver and adipose tissue<sup>1</sup> and in cholinergic neurons<sup>2,7</sup>. The structural basis of the function of ACLY remains unknown. Here we report high-resolution crystal structures of bacterial, archaeal and human ACLY, and use distinct substrate-bound states to link the conformational plasticity of ACLY to its multistep catalytic itinerary. Such detailed insights will provide the framework for targeting human ACLY in cancer<sup>8-11</sup> and hyperlipidaemia<sup>12,13</sup>. Our structural studies also unmask a fundamental evolutionary relationship that links citrate synthase, the first enzyme of the oxidative Krebs cycle, to an ancestral tetrameric citryl-CoA lyase module that operates in the reverse Krebs cycle. This molecular transition marked a key step in the evolution of metabolism on Earth.

Medical subject headings